Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameHinsang Group
Stock Code06893
Company Full NameTo be extracted
Industry消费零售
Principal Activities主要從事以多個品牌開發、營銷、銷售及分銷個人護理產品(洗浴及沐浴露、洗髮露、護髮素及護膚產品)、保健產品(健康補充品、兒童專用開奶茶等)及家居產品(洗衣液及消毒殺菌劑)。
Listing Date2014-10-16
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)香港九龍尖沙咀科學館道1號康宏廣場航天科技大廈12樓1213-1215室
Business Address (Hong Kong)香港 新界 元朗 宏業西街11號 科技中心12樓B室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.hinsanggroup.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 1.18 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2014-10-08 to 2014-10-08
Global Offering Shares200,000,000 shares
HK Public Offer Shares (Initial)20,000,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)180,000,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO800,000,000 shares
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 236,000,000

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
HK Market Cap HK$ 282.6M
Est. Threshold HK$ 9.39B
Analysis Result HK market cap below threshold, need +3223%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss Status純利約49.7百萬港元
Period-End Cash Balance港元65.1百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 HKD
Income Statement
Item 2012-032013-032014-03
Revenue 360,414235,114253,171
Cost of sales -258,945-136,704-110,830
Gross profit 101,46998,410142,341
Other income and gains, net 3402,2351,941
Selling and distribution expenses -29,079-31,515-34,529
Administrative expenses -44,219-43,892-47,923
Net finance costs -591-3,384-1,239
Profit before tax 27,09719,78161,175
Income tax expense -5,030-4,398-11,471
Profit for the year 22,06715,38349,704
Profit attributable to owners 22,06715,38349,704
Balance Sheet
Item 2012-032013-032014-03
Cash and cash equivalents 43,032101,19365,059
Trade and bills receivables 37,66231,96137,626
Inventories 29,51817,22612,999
Total current assets 117,645179,336115,684
Total assets 137,041203,326158,284
Total current liabilities 54,629101,29463,989
Total liabilities 56,815107,57463,989
Total equity 80,22695,75294,295
Equity attributable to owners 80,22695,75294,295
Interest-bearing borrowings 24,90283,7160
Cash Flow Statement
Item 2012-032013-032014-03
Net cash from operating activities 19,19628,85760,135
Net cash from investing activities -11,145-26,069-81,227
Net cash from financing activities 24,27355,383-14,900
Net increase in cash 32,32458,171-35,992
Depreciation of PP&E 1,9432,0231,771
Purchase of PP&E -4,063-7,069-13,408
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 1.37
First Day OpenHK$ 1.61
First Day Change16.10%
First Day Volume224482000.0
First Day Turnover335865000.0
Use of Proceeds
1、最多48 %或約104.4百萬港元將用作發掘與新品牌擁有人的業務合作機會,其中包括: 1.1約10%的所得款項凈額用作進行可行性研究、盡職審查及研究以于中國挑選潛在品牌擁有人; 1.2約28%的所得款項凈額用作進行各種市場推廣活動以提高與該業務合作相關的品牌知名度; 1.3約10%的所得款項凈額用作加強整個集團的銷售支持及客戶服務以加強于目標市場的業務; 2、最多25%或約54.3百萬港元將用作擴充我們的銷售及分銷網絡,其中包括: 2.1約10%的所得款項凈額用作透過招聘更多推廣員,以于中國直接向客戶銷售我們的自家品牌產品,藉此擴充我們的銷售團隊; 2.2約10%的所得款項凈額用作將我們的分銷網絡擴充至中國的其他省份; 2.3約5 %的所得款項凈額用作加強我們的推廣員培訓活動,藉此支持及協助我們擴充我的銷售網絡覆蓋,其中包括中國、臺灣、澳門、新加坡及馬來西亞。 3、最多15%或約32.6百萬港元將用作加強我們于中國的營銷及宣傳活動,例如: 3.1以多方面的營銷策略提高我們的自家品牌知名度; 3.2透過不同的媒體及渠道加強我們的廣告活動,以于中國宣傳我們的自家品牌產品; 3.3繼續聘用品牌大使以宣傳我們的自家品牌產品; 4、最多6 %或約13百萬港元將用作擴充我們的產品組合,例如: 4.1委聘中國醫藥機構以對我們的產品進行實驗室測試及取得相關的許可證; 4.2以我們的自家品牌開發更多新中成藥及健康補充食品; 5、余下的6 %余額或約13百萬港元將用作本集團的一般營運資金。

Underwriting Syndicate

Sole Sponsor (1)
Ample Capital Limited CE AFZ323
Joint Bookrunners (2)
Alpha Financial Group Limited CE ALW542 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956
Joint Lead Managers (4)
Alpha Financial Group Limited CE ALW542 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 EVERHOT SECURITIES LIMITED CE ABH246 ZHONGTAI INTERNATIONAL CAPITAL LIMITED CE BBY334

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman彭少衍—
Company Secretary蔡叔文—
No director data available.

Major Shareholders

Major Shareholders & Holdings彭少衍先生及關麗雯女士透過衍富持有緊隨資本化發行及股份發售完成後本公司全部已發行股本75%權益
About this page

This page shows Hinsang Group (06893) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect